All News
Filter News
Found 11,891 articles
-
In this third episode of Denatured's series on AI in drug discovery, we discuss patient behavior and its influence on clinical trials and AI models with guests from GSK, IQVIA, Exelixis and DataHow.
-
Generic Drugs Market Size to Lead an Estimated Value of USD 738.53 Billion by 2032
12/5/2023
The global generic drugs market size is estimated to grow from USD 439.37 billion in 2022 to lead an estimated value of USD 738.53 billion by 2032 at an expanding CAGR of 5.3% from 2023 to 2032.
-
CEO Emma Walmsley projects that the British biopharma’s Arexvy sales will exceed £1 billion in its first year on the market, leaving Pfizer’s Abrysvo respiratory syncytial virus vaccine far behind in the race.
-
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
12/1/2023
Silence Therapeutics plc announced Curtis Rambaran, MD, previously Silence’s Vice President, Head of Clinical Science, has been promoted to Chief Medical Officer, and Marie Wikström Lindholm, PhD, previously Silence’s Senior Vice President, Head of Molecular Design, has been promoted to Chief Scientific Officer, effective immediately.
-
Listen to this in-depth discussion on how AI can help identify end-to-end data weaknesses, as well as broader implications regarding the inevitability of human interaction, with guests from GSK, IQVIA, Exelixis and DataHow.
-
Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
11/28/2023
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company’s Board of Directors.
-
A year after exiting the U.S. market, GSK is setting the stage for the antibody-drug conjugate's possible return in relapsed/refractory multiple myeloma.
-
Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
11/24/2023
Sosei Group Corporation announces it has initiated discussions with GSK to regain full ownership of GSK4381406, a highly selective first-in-class, oral GPR35 agonist in development under a Global Collaboration and License Agreement with GSK as a potential new treatment for Inflammatory Bowel Diseases.
-
This is part one of a discussion focused upon data bias, accuracy, access and the future of AI in drug development. Topics explored are ROI, human bias, data challenges, data management plans, and human expertise.
-
Jemperli (dostarlimab for injection) plus carboplatin and paclitaxel approved in Canada as a treatment option for primary advanced or recurrent dMMR/MSI-H endometrial cancer
11/16/2023
GSK today announced that Health Canada has approved a new indication for Jemperli (dostarlimab for injection) in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systemic therapy, based on Part 1 of the pivotal RUBY study.
-
K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer
11/15/2023
K36 Therapeutics, Inc. today announced that Benjamin Winograd, MD, PhD, has been appointed Chief Medical Officer to lead the Medical and Clinical teams.
-
Under the potential $770.5 million deal announced Tuesday, Autifony Therapeutics is licensing to Jazz Pharmaceuticals two ion channel targets associated with neurological disorders.
-
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis(Phase II Multicenter Study is Proceeding Well with High Anticipation)
11/14/2023
XBiotech announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis.
-
Virology Market Size to Surpass USD 4.26 Billion by 2032
11/13/2023
The global virology market size was valued at USD 2.6 billion in 2022 and is estimated to surpass around USD 4.26 billion by 2032, growing at a healthy CAGR of 5.10% from 2023 to 2032.
-
NanoSyrinx appoints Anthony Johnson as Non-Executive Director
11/10/2023
NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director.
-
Tonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Highlights
11/9/2023
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the third quarter ended September 30, 2023, and provided an overview of recent operational highlights.
-
Pediatric Drugs Market Size to Garner Around USD 363.86 Billion by 2032
11/8/2023
The global pediatric drugs market size is predicted to garner around USD 363.86 billion by 2032 and is expanding at a CAGR of 12.2% over the forecast period 2023 to 2032.
-
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
11/7/2023
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T‑cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for the third quarter ended September 30, 2023.
-
Avalyn Strengthens Leadership Team with Key Appointments, including Dr. Craig Conoscenti as SVP, Clinical Development, and Jim Bishop as SVP, Business Operations
11/6/2023
Avalyn Pharma Inc. announced four leadership appointments across the organization, including lung disease drug development expert Craig Conoscenti, M.D., FCCP, ATSF, who will serve as senior vice president, clinical development.
-
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
11/6/2023
NeuroBo Pharmaceuticals, Inc. today announced the appointment of James P. Tursi , M.D., a pharmaceutical industry veteran, to its Board of Directors, effective November 1, 2023.